However, patients who had above average p38 (5-year survival rate: soft tissue MFH; 41.7%, bone MFH; 0%) had a worse prognosis than other patients (5-year survival rate: soft tissue MFH; 65.0%, bone MFH; 66.7%), but did not reach significant differences. These results may be due to small GSK461364 numbers of patients. Patients who had a higher than average expression of p38 MAPK (5-year survival rate: 50.0%) had a significantly worse prognosis than other patients (88.9%) (p = 0.0448) in LS patients. Therefore,
high expression of p38 MAPK may correlate with a worse prognosis especially for LS patients. Conclusions p38 MAPK may be a useful marker in the assessment of hTERT and prognosis. Given that more than 80% of sarcomas express p38 MAPK and hTERT, elucidation of the pathways and target genes of p38 MAPK in sarcomas will yield additional understandings into the pathogenesis of several sarcomas and may lead to novel therapeutic strategies for their treatment. References 1. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011–2015.PubMedCrossRef 2. de Lange T: Activation of telomerase in a human tumor.
Proc Natl Acad Sci USA 1994, 91:2882–2885.PubMedCrossRef 3. Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, Kodama T, Piatyszek MA, learn more Shay JW, Matsuura Y: Telomerase activity in Batimastat datasheet gastric cancer. Cancer Res 1995, 55:3258–3262.PubMed Aspartate 4. Tatsumoto N, Hiyama E, Murakami Y, Imamura Y, Shay JW, Matsuura Y, Yokoyama T: High telomerase activity is an independent
prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res 2000, 6:2696–2701.PubMed 5. Hiyama E, Hiyama K: Clinical utility of telomerase in cancer. Oncogene 2002, 21:643–649.PubMedCrossRef 6. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997, 17:498–502.PubMedCrossRef 7. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T, Ishikawa F: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998, 18:65–68.PubMedCrossRef 8. Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A: High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. Int J Cancer 2000, 89:63–68.PubMedCrossRef 9. Tomoda R, Seto M, Tsumuki H, Iida K, Yamazaki T, Sonoda J, Matsumine A, Uchida A: Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors. Cancer 2002, 95:1127–1133.